Show summary Hide summary
A commonly used label for a reproductive disorder is being replaced after an international expert panel concluded the old name mischaracterized the condition and hindered care. The proposal—renaming PCOS to polyendocrine metabolic ovarian syndrome, or PMOS—was published in The Lancet and unveiled this week at the European Congress of Endocrinology in Prague.
Experts say the new name matters now because it refocuses attention on the disorder’s broader hormonal and metabolic roots, not just ovarian cysts, with direct implications for diagnosis, treatment and stigma.
Why the change
Shipping hit by bunker fuel crunch as Iran conflict disrupts supplies
Yankees 2026 bring a new blueprint: how rivals and fans are affected
Researchers and clinicians argued that the term polycystic ovary syndrome has long suggested a primarily structural ovarian problem, when the condition typically involves a complex interaction of hormones, metabolism and ovarian function. That mismatch, they say, has shaped how clinicians look for and manage the disorder.
The renaming effort was developed with input from a wide coalition—dozens of professional and patient organizations and survey responses from more than 14,000 people living with the condition worldwide—aiming to better reflect the condition’s biology and lived experience.
Immediate consequences for patients and health systems
According to the authors, keeping the old label risks delayed diagnosis, fragmented care and unnecessary stigma. A clearer name could shift clinical guidelines, screening priorities and patient education.
- Diagnosis: Broader diagnostic thinking may prompt clinicians to assess metabolic and endocrine markers earlier rather than focusing mainly on ovarian imaging.
- Treatment pathways: Recognizing metabolic contributions could alter long-term management, including earlier attention to insulin resistance and cardiovascular risk.
- Health records and coding: The group is pursuing a global implementation plan to align disease classification, medical education and system-level coding with the new terminology.
- Patient experience: Reframing the condition may reduce misconceptions that the disorder is defined only by cysts or fertility problems.
What clinicians and patients should know
Now called PMOS in the proposal, the condition affects a significant proportion of people with ovaries—estimates suggest roughly one in eight. Symptoms vary but commonly include menstrual irregularities, weight changes, excess hair growth, acne and difficulties with conception.
Medical centers such as Johns Hopkins Medicine note that chronic, low-grade inflammation often accompanies the disorder and can worsen insulin resistance—linking the condition to metabolic health as much as to ovarian function.
When ovulation is impaired, the ovaries may develop fluid-filled follicles, sometimes labeled cysts; these can cause pain if they rupture. There is no single cure, but symptom-directed treatments—hormonal therapies, metabolic interventions and reproductive support—remain central to care.
Next steps and what to expect
The authors say a coordinated roll-out is underway to introduce the new name into clinical practice and education globally. That effort will include revised classification proposals, clinician training and adjustments to how health systems record and manage the diagnosis.
For patients and providers, the shift is likely to be gradual. Clinical guidelines, insurance coding and everyday language in clinics will take time to reflect the new terminology, but proponents hope the change will lead to earlier recognition and more integrated care.
